Multi‐omic study to unmask genes involved in prostate cancer development in a multi‐case family-Reference-Cited by-同舟云学术

Multi‐omic study to unmask genes involved in prostate cancer development in a multi‐case family

Published:2023-11-21 Issue: Volume: Page:
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Chica‐Redecillas Lucia¹²^ORCID,Cuenca‐Lopez Sergio¹^ORCID,Andres‐Leon Eduardo³^ORCID,Terron‐Camero Laura Carmen³^ORCID,Cano‐Gutierrez Blanca⁴^ORCID,Cozar Jose Manuel⁵,Lorente Jose Antonio¹⁶^ORCID,Vazquez‐Alonso Fernando⁵⁷^ORCID,Martinez‐Gonzalez Luis Javier¹^ORCID,Alvarez‐Cubero Maria Jesus¹²⁷^ORCID

Affiliation:

1. GENYO, Centre for Genomics and Oncological Research, Pfizer University of Granada Andalusian Regional Government, PTS Granada Granada Granada Spain

2. Department of Biochemistry Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, PTS Granada Granada Granada Spain

3. Bioinformatics Unit Institute of Parasitology and Biomedicine “López‐Neyra” Spanish National Research Council Granada Granada Spain

4. Nursery Service. University Hospital Clínico San Cecilio Granada Granada Spain

5. Urology Department University Hospital Virgen de las Nieves Granada Granada Spain

6. Legal Medicine and Toxicology Department Faculty of Medicine University of Granada PTS Granada Granada Granada Spain

7. Ibs, Biosanitary Research Institute Granada Granada Spain

Funder

Ministerio de Ciencia e Innovación

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12501

Reference10 articles.

1. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

2. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

3. Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1

4. Comprehensive characterisation of intronic mis-splicing mutations in human cancers

5. Mutations and mechanisms of WNT pathway tumour suppressors in cancer